Program
LYB005
A development code. Also written as “Low dose antigen of LYB005 without A01B adjuvant”, “Low dose antigen of LYB005 with A01B adjuvant” and “Middle dose antigen of LYB005 without A01B adjuvant”.
Its studies are mostly in Respiratory Syncytial Virus Infections · Infections, led by Guangzhou Patronus Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Patronus Biotech | 44 open or running | phase 3since Oct 26, 2026 | May 28, 2024 | Sep 2027phase 3 · NCT07908654 |
Also a collaborator on its studies: yantai-patronus-biotech-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2024First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT06442241 · 84 enrolled · Australia
- Mar 24, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06904222 · 90 enrolled · China
- Sep 27, 2025Phase 2 study in Respiratory Syncytial Virus InfectionsNCT07208461 · 700 enrolled · China
- Oct 26, 2026Phase 3 study in InfectionsPhase 3 reachedNCT07908654 · 25,000 planned · China
Ahead
- Sep 2027Primary completion: phase 3 study in InfectionsNCT07908654
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908654Infections · China | 3 | Not yet recruiting | Sep 2027 | 25,000 |
| NCT07208461Respiratory Syncytial Virus Infections · China | 2 | Active, not recruiting | Mar 2026 | 700 |
| NCT06904222Respiratory Syncytial Virus Infections · China | 1 | Active, not recruiting | Aug 2026 | 90 |
| NCT06442241Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Dec 30, 2025 | 84 |
How it is read
Names in the registry
- “Low dose antigen of LYB005 without A01B adjuvant”, 2 entries
- “Low dose antigen of LYB005 with A01B adjuvant”, 2 entries
- “Middle dose antigen of LYB005 without A01B adjuvant”, 2 entries
- “Middle dose antigen of LYB005 with A01B adjuvant”, 2 entries
- “High dose antigen of LYB005 without A01B adjuvant”, 2 entries
Codes read as this program: LYB005.
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 3 studies
- Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.